Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Orphan Drug 2022 Report
Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of drug development—outpacing the growth of the wider pharmaceuticals landscape, and accounting for an increasingly large proportion of novel drugs hitting the market. By 2026, orphans…
Report library
EP Vantage Pharma, Biotech and Medtech 2017 In Review
Report Highlights All major healthcare indices climbed in 2017, echoing wider stock market strength The $80bn spent on pharma & biotech acquisitions in 2017 makes…
EP Vantage 2018 Preview
Report Highlights M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals Another big year predicted for venture financing…
Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting
Key Report Themes Upside/downside radio metrics that identify companies that could either outperform in the coming years or are at risk Companies that could follow a…
